Germany Pneumococcal Vaccines Market to Reach $200.9 Million by 2026; Driven by Increasing Regulatory Approvals

The Germany pneumococcal vaccines market size is projected to reach USD 200.9 million by the year 2026. The market will benefit from the increasing number of favorable policies across the region. According to a report published by Fortune Business Insights, titled “Germany Pneumococcal Vaccines Market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026,” the market size was USD 170.0 million in 2018 and will exhibit a CAGR of 2.1% during the forecast period, 2019-2026.

Pneumococcal vaccines are used in vaccination against the bacteria Streptococcus pneumoniae. Pneumonia is a severe and potentially life-threatening disease that is caused by deadly bacteria. The pneumococcal vaccines are aimed in use for paediatrics as well as adults for treating acute and serious infections that are consequential to pneumonia. The severity of this disease has led to a higher emphasis on early adoption and treatment. Increasing investments on the research and development of newer vaccination options for the disease will bode well for the growth of the market in the coming years. Advances in ongoing clinical trials will bode well for the growth of the market. Increasing number of regulatory approvals, coupled with the growing investments in product R&D will aid the growth of the market in the forthcoming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/germany-pneumococcal-vaccines-101808

Key Segments in the Germany Pneumococcal Vaccines Market

• By Product Type: The market is segmented on the basis of product type into PCV10, PCV13, and PPSV23. Among these types, the PCV13 vaccines accounted for a dominant share in the Germany pneumococcal vaccines market. High clinical efficiency of the drug, coupled with the cost-effective nature, will aid the growth of the market in the coming years. The PCV13 was included in the National Immunization Program by an estimated 54 countries including developed countries such as the United States. The demand for PCV13 has risen dramatically in recent years, driven by the increasing applications of the product.


• By End User: On the basis of end users, the market is segmented into hospitals and clinics. Among these, the clinics segment held a dominant Germany pneumococcal vaccines market share in 2018. The growing patient preference in developed nations across Europe will contribute to the growth of this segment in the coming years. The increasing incidence of immunization of pediatric patients in clinics will aid the growth of this segment. According to The Standing Committee on Vaccination at the Robert Koch Institute (STIKO), around 90% immunization cases for pneumococcal vaccines in Germany are performed at clinics and physician offices. Besides clinics, the hospitals segment will witness considerable growth in the coming years.


• By Region: The market is segmented on the basis of regional demographics into several regions across Germany into Baden-Württemberg, Bayern, Nordrhein-Westfalen, Hessen, Niedersachsen, Sachsen, and Berlin. The market in Nordrhein-Westfalen is projected to hold the highest market share in the coming years, due to the increasing cases of pneumococcal vaccines across this region. Besides, these regions, the report analyzes the Germany Pneumococcal vaccines market trends across several other regions.

Pfizer and Merck & Co. Dominate the Market

The Germany pneumococcal market is consolidated in nature, with only a few players accounting for a high market share. The current pneumococcal polysaccharide vaccines scenario sees Pfizer holding a dominating share. A strong distribution network, combined with the growing prescription of PCV13 for patients, have favored the growth of these companies.

Some of the leading companies operating in the Germany pneumococcal vaccines market are:

• Pfizer


• Merck & Co. Inc.


• GlaxoSmithKline plc


• Sanofi

Key Industry Developments:

• August 2016: The German Committee on Vaccination announced an update in the German pneumococcal vaccination policy wherein pneumococcal vaccination were recommended through a sequential vaccination scheme.

The Germany Pneumococcal vaccines market is segmented on the basis of: